keyword
MENU ▼
Read by QxMD icon Read
search

neuroendocrine prostate cancer

keyword
https://www.readbyqxmd.com/read/29344129/update-on-radionuclide-therapy-in-oncology
#1
Cornelia Nitipir, Dana Niculae, Cristina Orlov, Maria Alexandra Barbu, Bogdan Popescu, Ana Maria Popa, Anca Mihaela Stoian Pantea, Adina Elena Stanciu, Bianca Galateanu, Octav Ginghina, Georgios Z Papadakis, Boris N Izotov, Demetrios A Spandidos, Aristides M Tsatsakis, Carolina Negrei
Unstable isotopes and their capacity to emit ionizing radiation have been employed in clinical practice not only for diagnostic, but also for therapeutic purposes, with significant contribution in several fields of medicine and primarily in the management of oncologic patients. Their efficacy is associated with their ability to provide the targeted delivery of ionizing radiation for a determined duration. These compounds can be used for curative or palliative treatment, as well as for a diagnostic-therapeutic (theranostic) approach...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29334357/differential-requirements-of-androgen-receptor-in-luminal-progenitors-during-prostate-regeneration-and-tumor-initiation
#2
Chee Wai Chua, Nusrat J Epsi, Eva Y Leung, Shouhong Xuan, Ming Lei, Bo I Li, Sarah K Bergren, Hanina Hibshoosh, Antonina Mitrofanova, Michael M Shen
Master regulatory genes of tissue specification play key roles in stem/progenitor cells and are often important in cancer. In the prostate, androgen receptor (AR) is a master regulator essential for development and tumorigenesis, but its specific functions in prostate stem/progenitor cells have not been elucidated. We have investigated AR function in CARNs (CAstration-Resistant Nkx3.1-expressing cells), a luminal stem/progenitor that functions in prostate regeneration. Using genetically-engineered mouse models and novel prostate epithelial cell lines, we find that progenitor properties of CARNs are largely unaffected by AR deletion, apart from decreased proliferation in vivo...
January 15, 2018: ELife
https://www.readbyqxmd.com/read/29297494/neuroendocrine-tumors-of-the-prostate
#3
Samson W Fine
Neuroendocrine (NE) differentiation in tumors of the prostate or in the setting of prostate cancer (PCa) is rare. A survey of these lesions is presented, including usual PCa with focal NE marker-positive cells, Paneth cell-like change, prostatic 'carcinoid', high-grade NE carcinoma, as well as other tumors that do not fit neatly into these categories. The most significant clinical and pathologic features, emerging molecular evidence and the importance of differentiating NE tumors involving the prostate from secondary involvement are highlighted...
January 2018: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/29289429/synaptophysin-expression-on-circulating-tumor-cells-in-patients-with-castration-resistant-prostate-cancer-undergoing-treatment-with-abiraterone-acetate-or-enzalutamide
#4
Sumanta K Pal, Miaoling He, Lin Chen, Lixin Yang, Raju Pillai, Przemyslaw Twardowski, JoAnn Hsu, Marcin Kortylewski, Jeremy O Jones
BACKGROUND: With the advent of secondary androgen receptor (AR)-targeted therapies in metastatic castration resistant prostate cancer (PC), nonadenocarcinoma PCs are becoming more prevalent. Many of these cancers express neuroendocrine markers, which may provide biomarkers for emergence of this disease state. We aimed to quantify the expression of synaptophysin (Syp) on circulating tumor cells (CTCs) from serial samples of patients being treated with abiraterone acetate or enzalutamide...
December 27, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/29284780/stress-during-puberty-facilitates-precancerous-prostate-lesions-in-adult-rats
#5
D Herrera-Covarrubias, G Coria-Avila, M E Hernandez, N Ismail
Puberty can be a critical period for the long-term development of diseases, especially for stress-related disorders that depend on neuroendocrine and immune responses. Some organs like the prostate are prone to diseases that result from neuroendocrine or immune challenges, such as cancer. AIM: In the present study, we assessed the long-term effects of an acute pubertal stressor (immune-challenge) on the development of precancerous lesions in adult rats, and compared them with testosterone-induced prostatic lesions...
December 2017: Experimental Oncology
https://www.readbyqxmd.com/read/29261618/metastasized-18f-dcfpyl-negative-prostatic-adenocarcinoma-without-neuroendocrine-differentiation
#6
Wouter A M Broos, Marielle Kocken, Friso M van der Zant, Remco J J Knol, Maurits Wondergem
A 76-year-old man with histopathologically proven prostate cancer (initial prostate-specific antigen 110 ng/mL, Gleason 3 + 4 = 7) received F-DCFPyL PET/CT for initial staging. Both the primary tumor and pathologically enlarged pelvic lymph nodes showed no increased F-DCFPyL uptake. Subsequent histopathologic lymph node biopsy revealed prostate cancer metastasis. Prostate-specific membrane antigen tracers, such as F-DCFPyL, are promising radiopharmaceuticals for prostate cancer imaging. False-negative prostate-specific membrane antigen PET/CT findings have been reported earlier for prostate tumors with neuroendocrine differentiation...
December 19, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29245927/a-bioinformatics-to-clinic-sequential-approach-to-analysis-of-prostate-cancer-biomarkers-using-tcga-datasets-and-clinical-samples-a-new-method-for-precision-oncology
#7
Hidekazu Yoshie, Anna S Sedukhina, Kimino Minagawa, Keiko Oda, Shigeko Ohnuma, Nobuyuki Yanagisawa, Ichiro Maeda, Masayuki Takagi, Hiroya Kudo, Ryuto Nakazawa, Hideo Sasaki, Toshio Kumai, Tatsuya Chikaraishi, Ko Sato
Biomarker-driven cancer therapy has met with significant clinical success. Identification of a biomarker implicated in a malignant phenotype and linked to poor clinical outcome is required if we are to develop these types of therapies. A subset of prostate adenocarcinoma (PACa) cases are treatment-resistant, making them an attractive target for such an approach. To identify target molecules implicated in shorter survival of patients with PACa, we established a bioinformatics-to-clinic sequential analysis approach, beginning with 2-step in silico analysis of a TCGA dataset for localized PACa...
November 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/29243324/validation-of-histone-deacetylase-3-as-a-therapeutic-target-in-castration-resistant-prostate-cancer
#8
Abigail B McLeod, James P Stice, Suzanne E Wardell, Holly M Alley, Ching-Yi Chang, Donald P McDonnell
BACKGROUND: Whereas the androgen receptor (AR) signaling axis remains a therapeutic target in castration-resistant prostate cancer (CRPC), the emergence of AR mutations and splice variants as mechanisms underlying resistance to contemporary inhibitors of this pathway highlights the need for new therapeutic approaches to target this disease. Of significance in this regard is the considerable preclinical data, indicating that histone deacetylase (HDAC) inhibitors may have utility in the treatment of CRPC...
December 15, 2017: Prostate
https://www.readbyqxmd.com/read/29236331/reduction-of-two-histone-marks-h3k9me3-and-h3k27me3-by-epidrug-induces-neuroendocrine-differentiation-in-prostate-cancer
#9
Eunsohl Lee, Jingcheng Wang, Younghun Jung, Frank C Cackowski, Russell S Taichman
Neuroendocrine prostate cancer (NE PCa) is an aggressive malignancy, often presenting with advanced metastasis. We previously reported that reduction of histone marks regulated by DNMT1 following epidrug (5-Azacitidine, 5-Aza) treatment controls induction of epithelial to mesenchymal (EMT) and a cancer stem cell (CSC) phenotype, which facilitates tumorigenesis in PCa cells. Here, we use the epidrug 5-Aza as a model for how histone marks may regulate the reprogramming of prostate adenocarcinoma into NE phenotypic cells...
December 13, 2017: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/29231196/prostate-cancer-damaged-good-targeting-dna-damage-repair-in-neuroendocrine-disease
#10
Annette Fenner
No abstract text is available yet for this article.
December 12, 2017: Nature Reviews. Urology
https://www.readbyqxmd.com/read/29230006/platinum-sensitivity-in-metastatic-prostate-cancer-does-histology-matter
#11
Michael S Humeniuk, Rajan T Gupta, Patrick Healy, Megan McNamara, Sundhar Ramalingam, Michael Harrison, Daniel George, Tian Zhang, Yuan Wu, Andrew J Armstrong
BACKGROUND: Platinum-based chemotherapy is effective in men with neuroendocrine prostate cancer (NEPC), but it is unclear whether histology (adenocarcinoma vs. non-adenocarcinoma NEPC variants) is predictive of platinum sensitivity. Given that NEPC exists as a spectrum, there may be men with adenocarcinoma who might benefit from platinum chemotherapy, particularly those men with DNA repair defects. METHODS: This was a retrospective study of all of the men seen at Duke University since 2005 who had metastatic castration-resistant prostate cancer (mCRPC) and were treated with a platinum agent...
December 11, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/29228680/long-noncoding-rna-miat-promotes-non-small-cell-lung-cancer-proliferation-and-metastasis-through-mmp9-activation
#12
I-Lu Lai, Chin-An Yang, Pei-Chin Lin, Wen-Ling Chan, Ya-Ting Lee, Ju-Chen Yen, Ya-Sian Chang, Jan-Gowth Chang
Long noncoding RNAs (lncRNAs) play crucial roles in carcinogenesis. Myocardial infarction-associated transcript (MIAT), originally isolated as a candidate gene for myocardial infarction, has been found to act as an oncogene in chronic lymphocytic leukaemias and neuroendocrine prostate cancer (NEPC); however, little is known about its expression pattern, biological function, and underlying mechanism in non-small cell lung cancer (NSCLC). In this study, we observed that MIAT expression was upregulated in NSCLC, and its overexpression was associated with advanced tumor stage...
November 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29220296/carcinosarcomas-and-related-cancers-tumors-caught-in-the-act-of-epithelial-mesenchymal-transition
#13
Angela Pang, Mariana Carbini, Andre L Moreira, Robert G Maki
In this review, we outline the biology and management of patients with carcinosarcomas and related malignancies, which are often included under the broader concept of sarcomatoid carcinomas. Carcinosarcomas are unusual tumors that are commonly gynecologic in origin, where they are referred to as malignant mixed Müllerian tumors, but may appear in any anatomic site. Although a variety of hypotheses have been presented as to the biphasic nature of these tumors, carcinosarcomas seem to represent the best example in human cancers of the concept of epithelial-mesenchymal transition (EMT), in which the two parts of the tumor are genomically related to one another, as opposed to the mesenchymal component that represents a second neoplasm or (benign) reactive process...
December 8, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29191973/blocking-the-feedback-loop-between-neuroendocrine-differentiation-and-macrophages-improves-the-therapeutic-effects-of-enzalutamide-mdv3100-on-prostate-cancer
#14
Chao Wang, Guang Peng, Hai Huang, Fei Liu, De-Pei Kong, Ke-Qin Dong, Li-He Dai, Zhe Zhou, Kai-Jian Wang, Jun Yang, Yan-Qiong Cheng, Xu Gao, Min Qu, Hongru Wang, Feng Zhu, Qin-Qin Tian, Dan Liu, Li Cao, Xingang Cui, Chuanliang Xu, Dan-Feng Xu, Yinghao Sun
PURPOSE: Androgen-deprivation therapy (ADT), including enzalutamide, induces resistance in prostate cancer (PCa); ADT resistance is associated with neuroendocrine differentiation (NED) and tumor-associated macrophages (TAMs). This study aimed to investigate the association between enzalutamide-induced NED and TAMs and its mechanism. EXPERIMENTAL DESIGN: The association between enzalutamide-induced NED and TAMs was investigated by immunohistochemistry using PCa tissues, enzalutamide-resistant mouse xenografts and a co-culture system...
November 30, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29156689/implications-of-pi3k-akt-inhibition-on-rest-protein-stability-and-neuroendocrine-phenotype-acquisition-in-prostate-cancer-cells
#15
Ruiqui Chen, Yinan Li, Ralph Buttyan, Xuesen Dong
Treatment-induced neuroendocrine prostate cancer (t-NEPC) is an aggressive subtype of prostate cancer (PCa) that arises as a consequence of rigorous androgen receptor (AR) pathway inhibition (ARPI) therapies. While the PI3K/AKT pathway has been investigated as a co-therapeutic target with ARPI for advanced PCa, whether this strategy can prevent tumor progression to t-NEPC remains unknown. Here, we report that PI3K/AKT inhibition alone reduces RE-1 silencing transcription factor (REST) protein expression and induces multiple NE markers in PCa cells...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29145267/osteoblastic-bone-metastases-from-neuroendocrine-tumor-net-of-unknown-origin-detected-by-18fluorocholine-pet-ct-and-its-comparison-with-68gallium-dotatoc-pet-ct-case-report-and-review-of-the-literature
#16
Alberto Bongiovanni, Federica Recine, Monica Celli, Giulia Marcantognini, Flavia Foca, Chiara Liverani, Valentina Fausti, Alessandro De Vita, Giacomo Miserocchi, Laura Mercatali, Dino Amadori, Toni Ibrahim
RATIONALE: Choline (CH) positron emission tomography (PET)/computed tomography (CT) with fluorine 18 (F) CH is increasingly used not only to evaluate patients with biochemically recurrent prostate cancer but also to assess metastatic lesions that are difficult or impossible to identify using more conventional modalities. Our experience with CH PET/CT has shown that it can also be used for many other malignancies. PRESENTING CONCERNS: A 71-year-old male with a neuroendocrine tumor (NET) of unknown origin showed osteoblastic bone metastases positive to F-CH PET...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29138344/targeting-the-mycn-parp-dna-damage-response-pathway-inneuroendocrine-prostate-cancer
#17
Wei Zhang, Bo Liu, Wenhui Wu, Likun Li, Bradley M Broom, Spyridon M Basourakos, Dimitrios Korentzelos, Yang Luan, Jianxiang Wang, Guang Yang, Sanghee Park, Abul K Azad, Xuhong Cao, Jeri Kim, Paul Corn, Christopher Logothetis, Ana M Aparicio, Arul M Chinnayan, Nora M Navone, Patricia Troncoso, Timothy C Thompson
PURPOSE: We investigated MYCN-regulated molecular pathways in castration-resistant prostate cancer (CRPC) classified by morphological criteria as adenocarcinoma or neuroendocrine to extend the molecular phenotype, establish driver pathways, and identify novel approaches to combination therapy for NEPC. RESULTS: Using comparative bioinformatics analyses of CRPC-Adeno and CRPC-Neuro RNA sequence data from public datasets and a panel of 28 PDX models we identified a MYCN-PARP-DNA damage response (DDR) pathway that is enriched in CRPC with neuroendocrine differentiation (NED) and CRPC-Neuro...
November 14, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29136407/phospholipase-d-inhibitors-reduce-human-prostate-cancer-cell-proliferation-and-colony-formation
#18
Amanda R Noble, Norman J Maitland, Daniel M Berney, Martin G Rumsby
BACKGROUND: Phospholipases D1 and D2 (PLD1/2) hydrolyse cell membrane glycerophospholipids to generate phosphatidic acid, a signalling lipid, which regulates cell growth and cancer progression through effects on mTOR and PKB/Akt. PLD expression and/or activity is raised in breast, colorectal, gastric, kidney and thyroid carcinomas but its role in prostate cancer (PCa), the major cancer of men in the western world, is unclear. METHODS: PLD1 protein expression in cultured PNT2C2, PNT1A, P4E6, LNCaP, PC3, PC3M, VCaP, 22RV1 cell lines and patient-derived PCa cells was analysed by western blotting...
November 14, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/29132337/gene-expression-signatures-of-neuroendocrine-prostate-cancer-and-primary-small-cell-prostatic-carcinoma
#19
Harrison K Tsai, Jonathan Lehrer, Mohammed Alshalalfa, Nicholas Erho, Elai Davicioni, Tamara L Lotan
BACKGROUND: Neuroendocrine prostate cancer (NEPC) may be rising in prevalence as patients with advanced prostate cancer potentially develop resistance to contemporary anti-androgen treatment through a neuroendocrine phenotype. While prior studies comparing NEPC and prostatic adenocarcinoma have identified important candidates for targeted therapy, most have relied on few NEPC patients due to disease rarity, resulting in thousands of differentially expressed genes collectively and offering an opportunity for meta-analysis...
November 13, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29126443/ubiquitin-c-terminal-hydrolase-isozyme-l1-is-associated-with-shelterin-complex-at-interstitial-telomeric-sites
#20
Aleksandar Ilic, Sumin Lu, Vikram Bhatia, Farhana Begum, Thomas Klonisch, Prasoon Agarwal, Wayne Xu, James R Davie
BACKGROUND: Ubiquitin C-terminal hydrolase isozyme L1 (UCHL1) is primarily expressed in neuronal cells and neuroendocrine cells and has been associated with various diseases, including many cancers. It is a multifunctional protein involved in deubiquitination, ubiquitination and ubiquitin homeostasis, but its specific roles are disputed and still generally undetermined. RESULTS: Herein, we demonstrate that UCHL1 is associated with genomic DNA in certain prostate cancer cell lines, including DU 145 cells derived from a brain metastatic site, and in HEK293T embryonic kidney cells with a neuronal lineage...
November 10, 2017: Epigenetics & Chromatin
keyword
keyword
83546
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"